The women s health initiative cohort studies and the population science research agenda
Download
1 / 47

112807WHICohortSt.. - PowerPoint PPT Presentation


  • 409 Views
  • Uploaded on

The Women’s Health Initiative, Cohort Studies, and the Population Science Research Agenda How can we obtain answers concerning health benefits and risks of behavior changes (interventions), and know that the answers are reliable?

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '112807WHICohortSt..' - issac


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
The women s health initiative cohort studies and the population science research agenda l.jpg

The Women’s Health Initiative, Cohort Studies, and the Population Science Research Agenda

  • How can we obtain answers concerning health benefits and risks of behavior changes (interventions), and know that the answers are reliable?

  • Major research tools each have important limitations (RCT; intermediate outcome trial; cohort and case-control studies)

  • Most population science research is outcome-centric, rather than intervention-centric.

  • Suitable forums for identifying priority research opportunities and needed methodology development are generally lacking.

Ross L. Prentice

Fred Hutchinson Cancer Research Center

and University of Washington


Major research tools each have important limitations l.jpg
Major Research Tools Population Science Research AgendaEach Have Important Limitations

Randomized controlled intervention trials

  • Cost, logistics, intervention adherence?

  • Only a small number are feasible at any time.

    Intermediate outcome clinical trials

  • Sufficiently comprehensive outcomes?

  • Methods to integrate data across many short-term outcomes?

  • Ability to replace full-scale clinical outcome trial? (surrogate outcomes)

    Observational studies

  • When are potential biases negligible? (confounding, selection, measurement error)

  • What assurance can be provided by replication in multiple populations?

  • How does reliability depend on nature of exposure variable/potential intervention and its measurement characteristics?


Some possible ways forward l.jpg
Some Possible Ways Forward Population Science Research Agenda

Comparative and joint analysis of RCT and Observational Study data

  • Differences may reflect residual bias in observational study (or differences in study populations; limitations of data analysis procedures; study power or adherence issues, or differential outcome ascertainment in either study type).

  • Joint analyses may usefully extend RCT results.

    Enhanced role of biomarkers to strengthen each type of study

  • Biomarkers to calibrate difficult-to-measure exposures in observational studies, and for explanatory analysis of intervention effects on RCTs.

  • Biomarkers to enhance comprehensiveness of intermediate outcome RCTs.

    Cooperative group to advise NIH and other funding sources on research

    opportunities and needs in chronic disease population research


Design of whi l.jpg
Design of WHI Population Science Research Agenda

os


Whi hormone program design l.jpg
WHI Hormone Program Design Population Science Research Agenda

Conjugated equine estrogen (CEE) 0.625 mg/d

YES

N= 10,739

Placebo

Hysterectomy

CEE 0.625 mg/d + medroxyprogesterone acetate (MDA) 2.5 mg/d

NO

N= 16,608

Placebo



Postmenopausal hormone therapy e p and cardiovascular disease l.jpg
Postmenopausal Hormone Therapy (E+P) and Cardiovascular Disease

Women’s Health Initiative study of estrogen plus progestin among postmenopausal women in the age range 50-79 at baseline*

CT OSAge-adj Age-adj

Placebo E+P HR Control E+P HR

Number of women 8102 8506 35,551 17,503

Number of events:

CHD 147 188 1.21 615 158 0.71

Stroke 107 151 1.33 490 123 0.77

VT 76 167 2.10 336 153 1.06

*Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb D, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J. American Journal of Epidemiology 162:404-414; 2005.


Slide8 l.jpg

Cox Model Disease

h(t; Z(t)) = hos(t)exp(x(t)/β)


Slide9 l.jpg

CVD Hazard Ratios for E+P Use, Disease

in Joint Analyses of Data from CT and OS Cohorts,

Controlling for Potential Confounding Factors

Adjusted for age (linear), ethnicity, bmi (categorical plus linear), education, smoking, age at menopause, physical functioning.


Slide10 l.jpg

E+P Hazard Ratio in the CT and OS as a Function of Time Disease

from Initiation of E+P Use

Coronary Heart Disease




Slide13 l.jpg

E+P Hazard Ratios (95% CIs) as a Function of Years from E+P Initiation, and Average HRs over Various Times from E+P Initiation, Assuming Common HR Functions in the CT and OS

Years from Coronary Heart Disease Venous Thromboembolism

E+P Initiation HR (95% CI) HR (95% CI)

< 2 1.56 (1.12, 2.19) 2.87 (1.89, 4.35)

2 – 5 1.16 (0.89, 1.51) 1.70 (1.28, 2.26)

> 5 0.81 (0.67, 0.99) 1.26 (1.02, 1.56)

Average HR (95% CI) Average HR (95% CI)

2 1.56 (1.12, 2.19) 2.87 (1.89, 4.35)

4 1.36 (1.09, 1.70) 2.28 (1.72, 3.03)

6 1.27 (1.04, 1.54) 2.07 (1.62, 2.63)

8 1.13 (0.96, 1.33) 1.83 (1.50, 2.23)

10 1.07 (0.92, 1.24) 1.71 (1.43, 2.05)


Slide14 l.jpg

Postmenopausal Estrogen-alone and Initiation, and Average HRs over Various Times from E+P Initiation, Assuming Common HR Functions in the CT and OS

Cardiovascular Disease

(Prentice RL, Langer R, Stefanick ML, et al. AJE 163:589-599,2006)

CT OS

Age-adj Age-Adj

Placebo E-alone HR Control E-alone HR

Number of women 5,429 5,310 16,411 21,920

Number of events:

CHD 201 217 0.96 548 421 0.68

Stroke 127 168 1.37 408 431 0.95

VT 86 111 1.33 274 265 0.78


Slide15 l.jpg

E-alone Initiation, and Average HRs over Various Times from E+P Initiation, Assuming Common HR Functions in the CT and OS

E+P

Years from Hormone

HR (95% CI)

HR (95% CI)

Treatment Initiation

Coronary Heart Disease

1.11 (0.73, 1.69)

1.58 (1.12, 2.24)

< 2

1.17 (0.88, 1.56)

1.19 (0.87, 1.63)

2 - 5

0.81 (0.62, 1.06)

0.86 (0.59, 1.26)

> 5

Hormone Therapy: HR in OS/HR in CT

0.89 (0.67, 1.19)

0.93 (0.64, 1.36)

Stroke

< 2

1.48 (0.89, 2.44)

1.41 (0.90, 2.22)

2 - 5

1.18 (0.83, 1.67)

1.14 (0.82, 1.59)

> 5

1.48 (1.06, 2.06)

1.12 (0.73, 1.72)

Hormone Therapy: HR in OS/HR in CT

0.68 (0.48, 0.97)

0.76 (0.49, 1.18)

Venous Thromboembolism

< 2

2.18 (1.15, 4.13)

3.02 (1.94, 4.69)

2 - 5

1.22 (0.80, 1.85)

1.85 (1.30, 2.65)

> 5

1.06 (0.72, 1.56)

1.47 (0.96, 2.24)

Hormone Therapy: HR in OS/HR in CT

0.82 (0.54, 1.23)

0.84 (0.55, 1.28)

Hormone Treatment Hazard Ratios (95% CIs) in the Estrogen (E-alone) Clinical Trial (CT); and in the Estrogen and Estrogen plus Progestin (E+P) Clinical Trials and Corresponding Observational Study Samples


Slide16 l.jpg

Coronary Heart Disease Hormone Treatment Hazard Ratios (95% CIs) among Women 50-59 Years of Age at Baseline from the OS with Adjustment using CT and OS Data on the Alternative Preparation


Slide17 l.jpg

CT CIs) among Women 50-59 Years of Age at Baseline from the OS with Adjustment using CT and OS Data on the Alternative Preparation

OS

Placebo

E-alone

Ratio

Control

E-alone

Ratio

Number of Women

5,429

5,310

14,458

21,663

Mean age

63.6

63.6

65.3

63.0

Mean years of follow-up

7.1

7.1

7.0

7.2

Number of Events

133

104

380

626

Age-Adjusted

Annualized Incidence (%)

0.35

0.28

0.80

0.36

0.41

1.13

CT

OS

Placebo

E+P

Ratio

Control

E+P

Ratio

Number of Women

8,102

8,506

32,755

17,382

Mean age

63.3

63.2

64.7

61.1

Mean years of follow-up

5.6

5.6

5.5

5.6

Number of Events

150

199

610

583

Age-Adjusted

Annualized Incidence (%)

0.33

0.42

1.25

0.33

0.65

1.94

Invasive Breast Cancer Incidence Rates in the Clinical Trial Hormone Trials (HT) and the Observational Study (OS) Subcohort*

E-alone

E+P

*From Prentice RL, Chlebowski R, Stefanick M, Manson J, Langer R, Pettinger M, Hendrix S, Hubbell A, Kooperberg C,

Kuller L, Lane D, McTiernan A, O’Sullivan MJ, Anderson G (2007). To appear, AJE (E-alone). Revised for AJE (E+P).

†Age-adjusted to the 5-year age distribution in the CT cohort.


Slide18 l.jpg

Invasive Breast Cancer Hazard Ratios for HT Use Adjusted for Potential Confounding Factors, in Combined Analyses of Data from the CT and OS

*Adjusted for age (linear), ethnicity, bmi (categorical and linear), education, smoking history, alcohol consumption, prior HT use, general health, physical activity, Gail risk score


Slide19 l.jpg

Breast Cancer Hazard Ratio Estimates according to Prior Postmenopausal Hormone Therapy Status and Years from Hormone Therapy Initiation


Slide20 l.jpg

Distribution of Women in the WHI Hormone Therapy Clinical Trials (CT), and in Corresponding Observational Study (OS) Subcohorts, According to Prior Use of Postmenopausal Hormone Therapy (HT) and Gap Time from Menopause to First Use of HT, Among Hormone Therapy Users

*Prior HT is defined relative to WHI enrollment in the CT and in the non-user groups in the OS. Prior HT in the user groups in the OS is defined relative to the beginning of the on-going HT episode at enrollment.


Slide21 l.jpg

Breast Cancer Hazard Ratio Estimates according to Prior Postmenopausal Hormone Therapy Status, Years from Hormone Therapy Initiation, and Gap Time from Menopause to Hormone Therapy Initiation, among Women Adhering to their Baseline Hormone Therapy Status

*Gap time in years from menopause to first use of HT


Slide22 l.jpg

Estimated Hazard Ratios (HRs) for CEE and CEE/MPA for Women Who Begin Hormone Therapy (HT) Immediately Following the Menopause and Adhere to their HT Regimen, from Combined Analysis of WHI Clinical Trial (CT) and Observational Study (OS) Data


Slide23 l.jpg

Estimated Hazard Ratios (HRs) for CEE and CEE/MPA for Women Who Begin Hormone Therapy (HT) Immediately Following the Menopause and Adhere to their HT Regimen, from Combined Analysis of WHI Clinical Trial (CT) and Observational Study (OS) Data (continued)


Slide24 l.jpg

Factors Included in Observational Study (OS) Hazard Ratio Analyses to Control Confounding. Corresponding Coefficients are Estimated Separately for Subsets of Women With or Without Prior Postmenopausal Hormone Therapy (HT)

*BMI, body mass index


Slide25 l.jpg

Factors Included in Observational Study (OS) Hazard Ratio Analyses to Control Confounding. Corresponding Coefficients are Estimated Separately for Subsets of Women With or Without Prior Postmenopausal Hormone Therapy (HT) (continued)

*NSAID, non-steroidal anti-inflammatory drug; OC, oral contraceptive

†These factors included only for women with prior hormone therapy.


Lessons from comparative and joint ct and os analysis of postmenopausal hormone therapy effects l.jpg
Lessons from Comparative and Joint CT and OS Analysis of Postmenopausal Hormone Therapy Effects

  • Ability to control prescription/confounding biases in OS may differ by clinical outcome (e.g., stroke, hip fracture).

  • Careful design and analysis methods needed to obtain accurate information from observational studies (allow for departures from proportional hazards, possible effect modification, …).

  • Clinical trial and observational study data may be able to be combined to obtain useful benefits and risk assessments (important subsets, longer durations, …).

  • Intervention trials may be needed if public health implications are sufficiently great.

  • Comparative trial and observational study results for other preventive interventions could be informative.


Enhanced role for biomarkers in population science research l.jpg
Enhanced Role for Biomarkers in Postmenopausal Hormone Therapy EffectsPopulation Science Research

  • Exposure biomarkers for difficult to measure exposures (e.g., dietary consumption or physical activity patterns)

  • High-dimensional biologic data to augment value of intermediate outcome trials

    e.g., Dietary fat and cancer


Slide28 l.jpg

Age-Adjusted Breast Cancer Incidence among Women of Ages 55-69 in 1980 versus per capita for Consumption in 1975


Slide29 l.jpg

Dietary Fat and 55-69 in 1980 versus per capita for Consumption in 1975

Postmenopausal Breast Cancer

Fat Intake Quintile

Case-control Studies

Howe et al (1990, JCNI) 1 1.20 1.24 1.24 1.46 (p<0.0001)

Cohort Studies

Hunter et al (1996, NEJM) 1 1.01 1.12 1.07 1.05 (p = 0.21)

Any reason to continue research on this topic?

Ability to adequately characterize and adjust for measurement error?


Slide30 l.jpg

Underreporting of Energy and Protein 55-69 in 1980 versus per capita for Consumption in 1975

(Heitmann and Lissner, 1995, BMJ)


Dietary change goals intervention group l.jpg
Dietary Change Goals: 55-69 in 1980 versus per capita for Consumption in 1975Intervention Group

  • 20% energy from fat

  • 5 or more fruit and vegetable servings daily

  • 6 or more grain servings daily

Photos courtesy of USDA Agricultural Research Service


Slide32 l.jpg

Mean (SD) of Nutrient Consumption by Randomization Group 55-69 in 1980 versus per capita for Consumption in 1975

*Difference significant at p<0.001 from a two sample t-test


Slide33 l.jpg

Comparison of Cancer Incidence Rates between Intervention and Comparison Groups in the Women’s Health Initiative (WHI) Dietary Modification Trial*

*Trial includes 19,541 women in the intervention group and 29,294 women in the comparison group.

†Weighted log-rank test (two-sided) stratified by age (5-year categories) and randomization status in the WHI hormone therapy trial. Weights increase linearly from zero at random assignment to a maximum of 1.0 at 10 years.

‡HR= hazard ratio; CI =confidence interval, from a proportional hazards model stratified by age (5-year categories), and randomization status in the WHI hormone therapy trial.


Slide34 l.jpg

  • Nature and magnitude of random and systematic bias likely and Comparison Groups in the Women’s Health Initiative (WHI) Dietary Modification Trial*

  • varies among assessment instruments.

  • Systematic bias may relate to many factors (e.g., age,

  • ethnicity, body mass, behavioral factors).

  • Bingham et al (2003, Lancet) report a positive association between breast cancer and total and fat when consumption was assessed using a 7-day food diary, but the association was modest and non-significant when consumption was assessed with a FFQ. Very similar results from 4-day food record and FFQ analyses among DM comparison group women (Freedman et al 2006, IJE).

  • Objective measures (biomarkers) are needed to make progress in this important research area. Biomarker assessments in substudies (such as DLW measures of total energy expenditure) can be used to calibrate self-report assessments.


Slide35 l.jpg
Nutrient Biomarker Substudy in the WHI DM Trial and Nutrition and Physical Activity Assessment Study in WHI Observational Study

  • 544 women completed two-week DLW protocol with urine and blood collection and with FFQ and other questionnaire data collection (50% intervention, 50% control). A 20% reliability subsample repeated protocol separated, by about 6 months from original data collection.

  • Biomarker study among 450 women in the WHI Observational Study for calibrating baseline FFQ, 4DFR, and PA questions, and for evaluating measurement properties of prominent dietary and physical activity assessment approaches (frequencies, records, and recalls) and their combination.


Slide36 l.jpg

Associations of Participants Characteristics with Measurement Error in Self-Reported Diet in the Women’s Health Initiative Nutritional Biomarkers Study


Slide37 l.jpg
Measurement Models for Nutritional Epidemiology Measurement Error in Self-Reported Diet in the Women’s Health Initiative Nutritional Biomarkers Study(Carroll, Freedman, Kaaks, Kipnis, Spiegelman, Rosner, Prentice…)

  • Recovery Biomarkers:

  • Xbiomarker = Z + e

  • Wself-report = a0 + a1Z + a2V + a3ZV + r + ε

  • Can estimate odds ratios (Sugar et al, 2007,Bmcs), or hazard ratios (Shaw et al, 2007), corresponding to Z from cohort data on W and subcohort data on X.

  • Concentration Biomarkers:

  • Xbiomarker = b0 + b1Z + s + e

  • Inability to disassociate actual intake ‘Z’ from person-specific bias ‘s’ is a major limitation.

  • Needed research:

  • Development of additional recovery-type biomarkers

  • Methodologic work (e.g., feeding study designs) to facilitate use of concentration biomarkers


Slide38 l.jpg
Regression Calibration Coefficients for Log-Transformed Total Energy, Total Protein and Percent Energy from Protein


Intermediate outcome trials having high dimensional responses l.jpg
Intermediate Outcome Trials Having Total Energy, Total Protein and Percent Energy from ProteinHigh-Dimensional Responses

  • Evaluate impact of candidate preventive interventions on high-dimensional response (e.g., plasma proteome)

  • Develop knowledge base to relate high-dimensional response to risk of a broad range of clinical outcomes

  • Predict intervention effects on clinical outcomes of interest, from high-dimensional response, to help determine whether a full-scale intervention trial is merited


Hormone therapy proteomics project l.jpg
Hormone Therapy Proteomics Project Total Energy, Total Protein and Percent Energy from Protein

Intact Protein Analysis System of Dr. Samir Hanash

50 E-alone women; 50 E+P women

Compare baseline to 1-year serum proteome

in pools of size 10


Slide41 l.jpg

Baseline Total Energy, Total Protein and Percent Energy from Protein

HT 1yr

Immunodepletion

(top six proteins)

Concentration, buffer exchange and labeling

Reduction with DTT

and Alkylation

SAMPLE A

Light Acrylamide

SAMPLE B

Heavy Acrylamide

(13Cx3=3Da shift)

SAMPLES MIXED

ANION EXCHANGE

CHROMATOGRAPHY

(12 pools)

REVERSE-PHASE

CHROMATOGRAPHY

(11 fractions / AEX)

12 x 11= 132 Fractions/IPAS

SHOTGUN LC-MS/MS

CONTROL

CONTROL

CONTROL

CONTROL

CANCER

CANCER

CANCER

CANCER

Immuno-depletion

(top six proteins)

Immuno-depletion

(top six proteins)

Immuno-depletion

(top six proteins)

Immuno-depletion

(top six proteins)

Concentration, buffer exchange and labeling

Concentration, buffer exchange and labeling

Concentration, buffer exchange and labeling

Concentration, buffer exchange and labeling

SAMPLE A

Light Acrylamide

SAMPLE A

Light Acrylamide

SAMPLE A

Light Acrylamide

SAMPLE A

Light Acrylamide

Reduction with DTT

and Alkylation

Reduction with DTT

and Alkylation

Reduction with DTT

and Alkylation

Reduction with DTT

and Alkylation

SAMPLE B

Heavy Acrylamide

(13Cx3=3Da shift)

SAMPLE B

Heavy Acrylamide

(13Cx3=3Da shift)

SAMPLE B

Heavy Acrylamide

(13Cx3=3Da shift)

SAMPLE B

Heavy Acrylamide

(13Cx3=3Da shift)

SAMPLES MIXED

SAMPLES MIXED

SAMPLES MIXED

SAMPLES MIXED

ANION EXCHANGE

CHROMATOGRAPHY

(12 pools)

ANION EXCHANGE

CHROMATOGRAPHY

(12 pools)

ANION EXCHANGE

CHROMATOGRAPHY

(12 pools)

ANION EXCHANGE

CHROMATOGRAPHY

(12 pools)

REVERSE-PHASE

CHROMATOGRAPHY

(10-12 fractions / AEX)

REVERSE-PHASE

CHROMATOGRAPHY

(10-12 fractions / AEX)

REVERSE-PHASE

CHROMATOGRAPHY

(10-12 fractions / AEX)

REVERSE-PHASE

CHROMATOGRAPHY

(10-12 fractions / AEX)

120-150 SHOTGUN LC-MS/MS

120-150 SHOTGUN LC-MS/MS

120-150 SHOTGUN LC-MS/MS

120-150 SHOTGUN LC-MS/MS

IPAS

5 E+P: 132 x 5=660

5 E: 132 x 5=660

Total: 1,320 fractions

Faca V et al., J. Proteome Res., 5, 2006, 2009-2018

“Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS”

Faca V et al., J. Proteome Res., 2007 accepted

“Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes”


Slide42 l.jpg

Data acquisition from 5 million mass spectra Total Energy, Total Protein and Percent Energy from Protein


Slide43 l.jpg

Protein quant_common Total Energy, Total Protein and Percent Energy from Protein

E+P

E

952

1,054

698


Slide45 l.jpg

Candidates for validation assay Total Energy, Total Protein and Percent Energy from Protein

-Angiogenin, RNASE4

-Insulin-like growth factor, IGF1

-Insulin-like growth factor binding protein1, IGFBP1

-Zinc-alpha-2-glycoprotein, AZGP1

Other candidates?


Population science research needs l.jpg
Population Science Research Needs Total Energy, Total Protein and Percent Energy from Protein

  • An enhanced preventive intervention development enterprise

  • Observational studies of maximal reliability for promising intervention concepts

  • Full-scale intervention trials when rationale strong enough, and public health potential sufficiently great

  • Vigorous methodology development (e.g., to incorporate exposure and intermediate outcome biomarkers into research agenda)

    Infrastructure to facilitate?


Population science cooperative group l.jpg
Population Science Cooperative Group Total Energy, Total Protein and Percent Energy from Protein

  • Identify preventive interventions that merit initial testing or full-scale evaluation

  • Receive and evaluate preventive trial proposals

  • Identify and facilitate needed methodologic research

    Group Composition

  • Population, basic and clinical scientists

  • Leaders in key areas for intervention development

  • Leaders in major chronic disease research areas

  • Representatives from within and outside of NIH


ad